Description
Donanemab is indicated for the treatment of Alzheimer’s disease for people with mild cognitive impairment or mild dementia stage of disease.
Donanemab was approved for medical use in the United States in July 2024. Most of the members of the FDA advisory panel had financial conflicts of interest. Treatment is intended for people with mild cognitive impairment or mild dementia stage of disease, which is the same population the treatment was studied in the clinical trials. Several public interest groups spoke out in FDA hearings against approval of the drug.
How to get access Kisunla (donanemab-azbt) for personal use ?
To get access to Kisunla (donanemab-azbt), you need a prescription from a doctor, as it is a prescription-only medication. Your prescription will be filled through a specialty pharmacy, which will handle insurance and coordinate delivery of the medication to you. Your doctor will also need to provide specific information for the prescription to be filled correctly.
However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Kisunla (donanemab-azbt) prices may fluctuate over time because of market dynamics and regulatory changes. It can be imported for personal use under “Named Patient Program” treatment in multiple countries, including the Singapore, Kuala Lumpur (Malaysia), Bangkok (Thailand), Jakarta, Surabaya, Bandung (Indonesia), Manila, Cebu (Philippines), Ho Chi Minh City, Hanoi (Vietnam), Yangon (Myanmar), Phnom Penh (Cambodia), Vientiane (Laos), UAE, Saudi Arabia, Argentina, Brazil, UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithuania, Greece, Spain, Zimbabwe, Australia, and New Zealand.
To order or inquire about Kisunla (donanemab-azbt) international access, you can contact Verve Biosciences – a trusted pharmaceutical exporter, supplier, and distributor of anti-cancer and specialty medications.
📧 Email: urgent@cancermedicinesnetwork.com
📞 Call or WhatsApp: 9910645395 or 9910645395
Note: Availability may vary by country and is subject to regulatory approvals.
